Line 12: |
Line 12: |
| |- | | |- |
| |8p11.2 amplification | | |8p11.2 amplification |
− | |''FGFR1'', ''ZNF703'' | + | |''[[FGFR1]]'', ''[[ZNF703]]'' |
| |2 | | |2 |
| |METABRIC IntClust6, ER positive | | |METABRIC IntClust6, ER positive |
| |- | | |- |
| |8q24 amplification | | |8q24 amplification |
− | |''MYC'' | + | |''[[MYC]]'' |
| |2 | | |2 |
| |METABRIC IntClust9, ER positive | | |METABRIC IntClust9, ER positive |
| |- | | |- |
| |9p24 amplification | | |9p24 amplification |
− | |''JAK2, CD274, PDCD1LG2'' | + | |''[[JAK2]], [[CD274]], [[PDCD1LG2]]'' |
| |2 | | |2 |
| |Enriched in TNBC | | |Enriched in TNBC |
| |- | | |- |
| |10q23.3 loss or LOH | | |10q23.3 loss or LOH |
− | |''PTEN'' | + | |''[[PTEN]]'' |
| |2 | | |2 |
| |Enriched in TNBC and in lobular carcinoma | | |Enriched in TNBC and in lobular carcinoma |
| |- | | |- |
| |11q13-q14 gain / amplification | | |11q13-q14 gain / amplification |
− | |''CCND1'', ''EMS1'', and others | + | |''[[CCND1]]'', ''[[EMS1]]'', and others |
| |2 | | |2 |
| |METABRIC IntClust2 | | |METABRIC IntClust2 |
| |- | | |- |
| |16q loss / LOH | | |16q loss / LOH |
− | |''CDH1'' | + | |''[[CDH1]]'' |
| |2 | | |2 |
| |METABRIC IntClust2, ER positive | | |METABRIC IntClust2, ER positive |
| |- | | |- |
| |17p loss / LOH | | |17p loss / LOH |
− | |''TP53'' | + | |''[[TP53]]'' |
| |2 | | |2 |
| |TNBC, basal-like intrinsic subtype | | |TNBC, basal-like intrinsic subtype |
| |- | | |- |
| |17q12 amplification | | |17q12 amplification |
− | |''ERBB2'' (''HER2'') | + | |''[[ERBB2]]'' (''HER2'') |
| |1 | | |1 |
| |METABRIC IntClust5, HER2-enriched | | |METABRIC IntClust5, HER2-enriched |
| |- | | |- |
| |17q21 amplification | | |17q21 amplification |
− | |''TOP2A'' | + | |''[[TOP2A]]'' |
| |2 | | |2 |
| |METABRIC IntClust5, HER2-enriched | | |METABRIC IntClust5, HER2-enriched |
| |- | | |- |
| |17q23 amplification (“17q distal amplicon”) | | |17q23 amplification (“17q distal amplicon”) |
− | |''RPS6KB'', others | + | |''[[RPS6KB]]'', others |
| |2 | | |2 |
| |METABRIC IntClust1 | | |METABRIC IntClust1 |
| |- | | |- |
| |19q12 | | |19q12 |
− | |''CCNE1'' | + | |''[[CCNE1]]'' |
| |2 | | |2 |
| |METABRIC IntClust5; HER2-enriched | | |METABRIC IntClust5; HER2-enriched |
| |- | | |- |
| |20q gain; 20q13 amp | | |20q gain; 20q13 amp |
− | |''AURKA'', ''GNAS'', ''ZNF217'' | + | |''[[AURKA]]'', ''[[GNAS]]'', ''[[ZNF217]]'' |
| |2 | | |2 |
| |METABRIC IntClust1, ER Positive | | |METABRIC IntClust1, ER Positive |
| |} | | |} |
| + | Abbreviations: TNBC, triple negative breast cancer. |
| + | |
| '''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics. | | '''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics. |
| {| class="wikitable" | | {| class="wikitable" |
Line 78: |
Line 80: |
| |'''Therapy Implication(s)''' | | |'''Therapy Implication(s)''' |
| |- | | |- |
− | |''AKT1'' | + | |''[[AKT1]]'' |
| |2 | | |2 |
| |Metastatic BC | | |Metastatic BC |
| |AKT inhibitors | | |AKT inhibitors |
| |- | | |- |
− | |''ATM'' | + | |''[[ATM]]'' |
| |1 | | |1 |
| |Possible hereditary risk; TNBC | | |Possible hereditary risk; TNBC |
| |PARP inhibitors (germline) | | |PARP inhibitors (germline) |
| |- | | |- |
− | |''BRCA1, BRCA2'' | + | |''[[BRCA1 syndrome|BRCA1]], [[BRCA2 syndrome|BRCA2]]'' |
| |1 | | |1 |
| |Often hereditary risk; TNBC | | |Often hereditary risk; TNBC |
| |Platinum based therapy; PARP inhibitors (germline) | | |Platinum based therapy; PARP inhibitors (germline) |
| |- | | |- |
− | |''CBFB'' | + | |''[[CBFB]]'' |
| |2 | | |2 |
| |ER-positive, Metastatic BC | | |ER-positive, Metastatic BC |
| | | | | |
| |- | | |- |
− | |''CCND1, CCNE1''* | + | |''[[CCND1]], [[CCNE1]]''* |
| |2 | | |2 |
| |HER2-enriched | | |HER2-enriched |
| |CDK4/6 inhibitors | | |CDK4/6 inhibitors |
| |- | | |- |
− | |''CDK4, CDK6''* | + | |''[[CDK4]], [[CDK6]]''* |
| |2 | | |2 |
| |ER-positive, Metastatic BC | | |ER-positive, Metastatic BC |
| |CDK4/6 inhibitors | | |CDK4/6 inhibitors |
| |- | | |- |
− | |''CDH1'' | + | |''[[CDH1]]'' |
| |1 | | |1 |
| |Lobular histology; Possible hereditary risk | | |Lobular histology; Possible hereditary risk |
| | | | | |
| |- | | |- |
− | |''CDKN2A'' | + | |''[[CDKN2A]]'' |
| |2 | | |2 |
| |Metastatic BC | | |Metastatic BC |
| | | | | |
| |- | | |- |
− | |''CHEK2'' | + | |''[[CHEK2]]'' |
| |1 | | |1 |
| |Often hereditary risk | | |Often hereditary risk |
| |PARP inhibitors (germline) | | |PARP inhibitors (germline) |
| |- | | |- |
− | |''ERBB2''* | + | |''[[ERBB2]]''* |
| |1 | | |1 |
| |Rare activating sequence alterations; kinase domain resistance mutations; HER2-enriched | | |Rare activating sequence alterations; kinase domain resistance mutations; HER2-enriched |
| |HER2-targeted therapy | | |HER2-targeted therapy |
| |- | | |- |
− | |''ESR1'' | + | |''[[ESR1]]'' |
| |1 | | |1 |
| |Metastatic ER-positive | | |Metastatic ER-positive |
| |Hormone therapy resistance | | |Hormone therapy resistance |
| |- | | |- |
− | |''FGFR1-4'' | + | |''[[FGFR1]], [[FGFR2]], [[FGFR3]], [[FGFR4]]'' |
| |2 | | |2 |
| |ER-positive | | |ER-positive |
| |FGFR inhibitors | | |FGFR inhibitors |
| |- | | |- |
− | |''FOXA1'' | + | |''[[FOXA1]]'' |
| |2 | | |2 |
| |ER-positive, Luminal subtype, lobular histology | | |ER-positive, Luminal subtype, lobular histology |
| | | | | |
| |- | | |- |
− | |''GATA3'' | + | |''[[GATA3]]'' |
| |2 | | |2 |
| |ER-positive, Luminal subtype | | |ER-positive, Luminal subtype |
| | | | | |
| |- | | |- |
− | |''JAK2''* | + | |''[[JAK2]]''* |
| |2 | | |2 |
| |TNBC | | |TNBC |
| |JAK2 inhibitors, immunotherapy | | |JAK2 inhibitors, immunotherapy |
| |- | | |- |
− | |''MAP2K4'' | + | |''[[MAP2K4]]'' |
| |2 | | |2 |
| |Metastatic BC | | |Metastatic BC |
| | | | | |
| |- | | |- |
− | |''MAP3K1'' | + | |''[[MAP3K1]]'' |
| |2 | | |2 |
| |ER-positive, Metastatic BC | | |ER-positive, Metastatic BC |
| | | | | |
| |- | | |- |
− | |''MYC''* | + | |''[[MYC]]''* |
| |2 | | |2 |
| | | | | |
| | | | | |
| |- | | |- |
− | |''NBN'' | + | |''[[NBN]]'' |
| |1 | | |1 |
| |Possible hereditary risk | | |Possible hereditary risk |
| |PARP inhibitors (germline) | | |PARP inhibitors (germline) |
| |- | | |- |
− | |''NF1'' | + | |''[[NF1]]'' |
| |1 | | |1 |
| |Possible hereditary risk | | |Possible hereditary risk |
| |mTOR/PI3K/AKT inhibitors (germline) | | |mTOR/PI3K/AKT inhibitors (germline) |
| |- | | |- |
− | |''NTRK1-3'' | + | |''[[NTRK1]], [[NTRK2]], [[NTRK3]]'' |
| |1 | | |1 |
| | | | | |
| |NTRK inhibitors | | |NTRK inhibitors |
| |- | | |- |
− | |''PALB2'' | + | |''[[PALB2]]'' |
| |1 | | |1 |
| |Often hereditary risk | | |Often hereditary risk |
| |PARP inhibitors (germline) | | |PARP inhibitors (germline) |
| |- | | |- |
− | |''PIK3CA'' | + | |''[[PIK3CA]]'' |
| |1 | | |1 |
| |ER-Positive, Luminal subtype | | |ER-Positive, Luminal subtype |
| |PI3K inhibitors for selected hotspot mutations; acquired hormone resistance | | |PI3K inhibitors for selected hotspot mutations; acquired hormone resistance |
| |- | | |- |
− | |''PTEN'' | + | |''[[PTEN]]'' |
| |2 | | |2 |
| |Loss in lobular BC | | |Loss in lobular BC |
Line 200: |
Line 202: |
| |mTOR/PI3K/AKT inhibitors; radiation contraindicated | | |mTOR/PI3K/AKT inhibitors; radiation contraindicated |
| |- | | |- |
− | |''RB1'' | + | |''[[RB1]]'' |
| |2 | | |2 |
| |Metastatic BC | | |Metastatic BC |
| |Acquired hormone resistance | | |Acquired hormone resistance |
| |- | | |- |
− | |''STK11'' | + | |''[[STK11]]'' |
| |1 | | |1 |
| |Possible hereditary risk | | |Possible hereditary risk |
| | | | | |
| |- | | |- |
− | |''TBX3'' | + | |''[[TBX3]]'' |
| |2 | | |2 |
| |Lobular BC | | |Lobular BC |
| | | | | |
| |- | | |- |
− | |''TOP2A''* | + | |''[[TOP2A]]''* |
| |2 | | |2 |
| | | | | |
| |Anthracycline inhibitors | | |Anthracycline inhibitors |
| |- | | |- |
− | |''TP53'' | + | |''[[TP53]]'' |
| |1 | | |1 |
| |TNBC, HER2-enriched, Metastatic BC | | |TNBC, HER2-enriched, Metastatic BC |
Line 258: |
Line 260: |
| |'''Associated Syndrome; Breast Cancer Subtype''' | | |'''Associated Syndrome; Breast Cancer Subtype''' |
| |- | | |- |
− | |''ATM'' | + | |''[[ATM]]'' |
| |Ataxia telangiectasia syndrome | | |Ataxia telangiectasia syndrome |
| |- | | |- |
− | |''BARD1'' | + | |''[[BARD1]]'' |
| |TNBC | | |TNBC |
| |- | | |- |
| |''BRCA1'' | | |''BRCA1'' |
− | |BRCA-Related Breast/ Ovarian Cancer Syndrome; TNBC | + | |[[BRCA1 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC |
| |- | | |- |
| |''BRCA2'' | | |''BRCA2'' |
− | |BRCA-Related Breast/ Ovarian Cancer Syndrome; TNBC | + | |[[BRCA2 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC |
| |- | | |- |
− | |''CDH1'' | + | |''[[CDH1]]'' |
| |Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer | | |Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer |
| |- | | |- |
− | |''CHEK2'' | + | |''[[CHEK2]]'' |
| |Inherited breast cancer | | |Inherited breast cancer |
| |- | | |- |
− | |''NBN'' | + | |''[[NBN]]'' |
| |Nijmegen Breakage Syndrome | | |Nijmegen Breakage Syndrome |
| |- | | |- |
− | |''NF1'' | + | |''[[NF1]]'' |
| |Neurofibromatosis type 1 | | |Neurofibromatosis type 1 |
| |- | | |- |
− | |''PALB2'' | + | |''[[PALB2]]'' |
| |Fanconi anemia | | |Fanconi anemia |
| |- | | |- |
− | |''PTEN'' | + | |''[[PTEN]]'' |
| |Cowden syndrome | | |Cowden syndrome |
| |- | | |- |
− | |''RAD51C'' | + | |''[[RAD51C]]'' |
| |TNBC | | |TNBC |
| |- | | |- |
− | |''RAD51D'' | + | |''[[RAD51D]]'' |
| |TNBC | | |TNBC |
| |- | | |- |
− | |''STK11'' | + | |''[[STK11]]'' |
| |Peutz-Jeghers syndrome | | |Peutz-Jeghers syndrome |
| |- | | |- |
− | |''TP53'' | + | |''[[TP53]]'' |
| |Li-Fraumeni syndrome | | |Li-Fraumeni syndrome |
| |} | | |} |
| + | Abbreviations: TNBC, triple negative breast cancer. |